UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)

Leukemia, 2022-05, Vol.36 (5), p.1450-1450

2022

Link zum Volltext

Verfügbarkeit prüfen

In ®Entresto we trust

Cardio-oncology (London, England), 2020-11, Vol.6 (1), p.25-25, Article 25

2020

Link zum Volltext

Verfügbarkeit prüfen

Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study

Chemotherapy (Basel), 2018-01, Vol.63 (2), p.55-63

2018

Link zum Volltext

Verfügbarkeit prüfen

Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study

Clinical and translational science, 2023-10, Vol.16 (10), p.1876-1885

2023

Link zum Volltext

Verfügbarkeit prüfen

Doxorubicin degradation in cardiomyocytes

The Journal of pharmacology and experimental therapeutics, 2007-07, Vol.322 (1), p.408

2007

Link zum Volltext

Verfügbarkeit prüfen

The Reality of Pixantrone in Real Life

Acta haematologica, 2021-05, Vol.144 (3), p.244-245

2021

Link zum Volltext

Verfügbarkeit prüfen

Cancer drugs and QT prolongation: weighing risk against benefit

Expert opinion on drug safety, 2017-10, Vol.16 (10), p.1099-1102

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of low dose ponatinib in a case of Ph‐positive acute lymphoblastic leukaemia

British journal of haematology, 2019-10, Vol.187 (1), p.e15-e17

2019

Link zum Volltext

Verfügbarkeit prüfen

Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life

Chemotherapy (Basel), 2021-06, Vol.66 (1-2), p.47-52

2021

Link zum Volltext

Verfügbarkeit prüfen

From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction

JACC CardioOncology, 2022-03, Vol.4 (1), p.139-140

2022

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Cardiotoxicity of Targeted Cancer Drugs: Concerns, “The Cart Before the Horse,” and Lessons from Trastuzumab

Current cardiology reports, 2019-04, Vol.21 (5), p.40-40, Article 40

2019

Link zum Volltext

Verfügbarkeit prüfen

N°94 – Reduction of EEG connectivity induced by cenobamate correlates with clinical and cognitive outcomes

Clinical neurophysiology, 2023-06, Vol.150, p.e101-e101

2023

Link zum Volltext

Verfügbarkeit prüfen

From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach

JACC CardioOncology, 2022-03, Vol.4 (1), p.139-140

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and tolerability of a novel oral nutritional supplement in healthy volunteers

Clinical nutrition (Edinburgh, Scotland), 2021-03, Vol.40 (3), p.946-955

2021

Link zum Volltext

Verfügbarkeit prüfen

Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy

Chemotherapy (Basel), 2018, Vol.63 (1), p.35-38

2018

Link zum Volltext

Verfügbarkeit prüfen

Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart

The Journal of biological chemistry, 2006-04, Vol.281 (16), p.10990-11001

2006

Link zum Volltext

Verfügbarkeit prüfen

Isavuconazole: Case Report and Pharmacokinetic Considerations

Chemotherapy (Basel), 2018-01, Vol.63 (5), p.253-256

2018

Link zum Volltext

Verfügbarkeit prüfen

Low Level Tumor Necrosis Factor-Alpha Protects Cardiomyocytes Against High Level Tumor Necrosis Factor-Alpha: Brief Insight into a Beneficial Paradox

Cardiovascular toxicology, 2014-12, Vol.14 (4), p.387-392

2014

Link zum Volltext

Verfügbarkeit prüfen

Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy

Cancer research (Chicago, Ill.), 2001-12, Vol.61 (23), p.8422-8428

2001

Link zum Volltext

Verfügbarkeit prüfen

Oxidative Degradation of Cardiotoxic Anticancer Anthracyclines to Phthalic Acids

The Journal of biological chemistry, 2004-02, Vol.279 (7), p.5088-5099

2004

Link zum Volltext

Verfügbarkeit prüfen

Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment

Blood, 2011-11, Vol.118 (21), p.4966-4966

2011

Link zum Volltext

Verfügbarkeit prüfen

What is cardiotoxicity?

Progress in pediatric cardiology, 2014-09, Vol.36 (1), p.3-6

2014

Link zum Volltext

Verfügbarkeit prüfen

Tumour Necrosis Factor Alpha (TNF[alpha]) Cardiomyocyte Preconditioning: Clues to Explain Anti-TNF[alpha] Agents Contraindication in Severe Heart Failure

Clinical drug investigation, 2013-08, Vol.33 (2), p.S118

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 28

Suche als RSS-Feed

Aktive Filter

ThemaChemistry, Multidisciplinary

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)
Buchkapitel
(1)

Sprache

Englisch
(28)
Japanisch
(2)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

In ®Entresto we trust

Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study

Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study

P487: MIDOSTAURIN PLASMA EXPOSURE IN PATIENTS WITH FLT3‐MUT ACUTE MYELOID LEUKEMIA UNDERGOING POSACONAZOLE PROPHYLAXIS DURING INDUCTION TREATMENT: A PROSPECTIVE MULTICENTRE STUDY FROM THE SEIFEM GROUP

Doxorubicin degradation in cardiomyocytes

High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study

The Reality of Pixantrone in Real Life

Cancer drugs and QT prolongation: weighing risk against benefit

Efficacy and safety of low dose ponatinib in a case of Ph‐positive acute lymphoblastic leukaemia

Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life

From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction

Correction to: Cardiotoxicity of Targeted Cancer Drugs: Concerns, “The Cart Before the Horse,” and Lessons from Trastuzumab

N°94 – Reduction of EEG connectivity induced by cenobamate correlates with clinical and cognitive outcomes

From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach

Safety and tolerability of a novel oral nutritional supplement in healthy volunteers

Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy

Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart

Isavuconazole: Case Report and Pharmacokinetic Considerations

Low Level Tumor Necrosis Factor-Alpha Protects Cardiomyocytes Against High Level Tumor Necrosis Factor-Alpha: Brief Insight into a Beneficial Paradox

Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy

Oxidative Degradation of Cardiotoxic Anticancer Anthracyclines to Phthalic Acids

Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment

What is cardiotoxicity?

Tumour Necrosis Factor Alpha (TNF[alpha]) Cardiomyocyte Preconditioning: Clues to Explain Anti-TNF[alpha] Agents Contraindication in Severe Heart Failure

Aktive Filter

Suchergebnisse filtern